Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Acquisition of exclusive commercialization rights for European markets
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Subscribe To Our Newsletter & Stay Updated
